Duration of Trastuzumab. In matters of the heart, one size may not fit all?
- PMID: 26185034
- DOI: 10.1016/j.ejca.2015.06.004
Duration of Trastuzumab. In matters of the heart, one size may not fit all?
Abstract
The PHARE trial was initially reported in 2013 and demonstrated that 6 months of Trastuzumab therapy was inferior to 12 months of therapy in terms of reducing risk of Her2+ breast cancer recurrence. Updated results of this study have been presented and demonstrate that while there is a reduction in breast cancer risk with 12 months of therapy, there is an increase in risk of cardiac events. This may have implications for patient selection, and certainly has implications for future studies. As cardiac outcomes of cancer therapies become increasingly prevalent, an integrated approach to trial design and clinical management is needed.
Keywords: Breast cancer; Cardio-toxicity; Congestive heart failure; Trastuzumab.
Copyright © 2015. Published by Elsevier Ltd.
Comment on
-
Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.Eur J Cancer. 2015 Sep;51(13):1660-6. doi: 10.1016/j.ejca.2015.05.028. Epub 2015 Jul 7. Eur J Cancer. 2015. PMID: 26163096 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
